Experimental Design: Global and membranous endoglin expression was evaluated in multiple ovarian cancer lines. In vitro, the effects of siRNA-mediated endoglin knockdown with and without chemotherapy were evaluated by MTT assay, cell-cycle analysis, alkaline comet assay, γ-H2AX foci formation, and qPCR. In an orthotopic mouse model, endoglin was targeted with chitosan-encapsulated siRNA with and without carboplatin.
Introduction
Epithelial ovarian carcinoma (EOC) remains the most lethal gynecologic malignancy. 1 While initial response to first-line therapy (consisting of surgical cytoreduction and combination platinum/taxane therapy) is usually effective, the majority of patients will ultimately recur with chemotherapy-resistant cancer and succumb to disease. This emphasizes the need for novel therapies aimed at targeting the population of cancer cells most resistant to initial therapy.
Endoglin (ENG) is a 180kDa disulfide-linked homodimer transmembrane protein most prominently expressed on proliferating endothelial cells. It is a well-characterized angiogenic marker that is upregulated during angiogenesis, and is overexpressed in vascular endothelium in malignancies including ovarian, leukemia, gastrointestinal stromal tumors (GIST), melanoma, and laryngeal cancers, but is rarely expressed in non-endothelial cells. [2] [3] It is a co-receptor of TGFBR2 that binds TGF-B and is an important mediator of fetal vascular/endothelial development. 4 Recently, anti-angiogenic agents have received extensive attention as new therapeutic modalities, and CD105 has become an additional target by which intratumoral angiogenesis may be targeted. [5] [6] However, endoglin may serve in a capacity beyond angiogenesis alone. Studies in GIST 7 and breast cancer 8 suggest that endoglin is upregulated not only in tumor endothelial cells, but also in actual tumor cells, and is associated with poor prognosis. Soluble endoglin has also been noted in ovarian cancer ascites, 9 and increased endoglin expression in ovarian cancer endothelial cells is associated with poor prognosis. 10 Additionally, we have recently shown that while endoglin is rarely expressed in primary ovarian cancer cells, it is frequently expressed in recurrent platinum-resistant tumor cells, as compared to the primary untreated tumor. 11 These findings suggest a broader role of endoglin in tumor cell biology beyond that of endothelial expression alone. The goal of our current study is to evaluate peroxidase was blocked with 3% H2O2 in methanol for 15min at RT. The slides were incubated in 10% normal goat serum for 1 hr at RT. The primary anti-endoglin antibody (Sigma HPA011862) was diluted in 10% normal goat serum at 1:50. The slides were kept at 4°C overnight. Biotin-labeled secondary antibody was applied on cells at the concentration of 1:2000 for 1hr at RT, followed by avidin-biotin peroxidase buffer. DAB (3,3'-diaminobenzidine) was used as chromophore to detect the staining. To visualize endoglin expression in tumor sections, formalin-fixed paraffin-embedded tissue was cut in sections of 5uM thickness. Slides were warmed for 15 minutes and sequentially deparaffinized. Antigen retrieval was carried out in Citrate buffer (pH6.0) in a pressure cooker at high pressure for 5 min. Endogenous peroxidase was quenched by 3% H2O2 in methanol for 15 min. Slides were incubated in 10% normal goat serum for 1hr at RT. Slides were then incubated (4°C, Overnight) in antibody against endoglin (Sigma HPA011862) in 10% normal goat serum at 1:200 dilution. Detection was carried out using biotin labeled secondary antibody against rabbit at dilution of 1:2000 incubated at RT for 1 hr, followed by avidin-biotin peroxidase buffer. DAB (3,3'-diaminobenzidine) was used as chromophore.
Flow cytometry. After trypsinisation and centrifugation, the cell pellet was washed and resuspended in washing buffer (PBS containing 2% FBS and 0.1% sodium azide).1x10 7 cells were resuspended in 50μls of 10% goat buffer for 1hr kept on ice. Cells were incubated in antibody against endoglin 1:100 (Sigma HPA011862) in 10% goat serum for 1hr on ice. Alexa-488-conjugated anti rabbit antibody was applied on cells for 30 minutes and incubated on ice.
The cells were washed twice in PBS and analyzed by FACS. should not affect murine endoglin expression. Lipofectamine was added to 5μg siRNA at a 3:1 v/v ratio (or as otherwise specified, as in Figure 1E ) were incubated for 20 min at RT, added to cells in serum-free RPMI to incubate for 12 hours in 6-well plates, then maintained in 10% FBS/RPMI for an additional 12 hours, trypsinized and re-plated on a 96-well plate at a concentration of 2,000 cells per well. Cells were treated with vehicle or increasing doses of carboplatin or paclitaxel to generate an IC 50 curve. After 5 days, cells were washed and incubated with MTT reagent (Sigma) for 2 hours at 37°C. Media was then removed, cells dissolved in DMSO, and optical density measurements at 570 nm read with a spectrophotometer. Alkaline comet assay. ES2 cells (n=400,000 in 6-well plate) were transfected with endoglin and control siRNA. Twenty-four hours following transfection, cells were exposed to cisplatin without supplemental SVF at a concentration of 1μM (the approximate IC80 level for this line) for either 1 or 4 hours, carefully rinsed to remove the drug, and cultured in regular media.
Vehicle or control siRNA were included in all experiments. At the indicated time points, cells were collected and subjected to alkaline comet assay according to the manufacturer's instructions (catalog # 4250-050-K; Trevigen). Briefly, cells were combined with low melting agarose onto CometSlides (Trevigen). After lysis, cells were subjected to electrophoresis and stained with SYBR green. Subsequently, cells were visualized using fluorescent microscopy (Carl Zeiss, Thornwood, NY). At least 200 comet images were analyzed for each time point using Comet Score software (version 1.5; TriTek Corp.). The number of tail-positive cells with small and large nuclei was manually counted by an examiner blinded to treatment group, and expressed as a percentage of all cells evaluated. Experiments were repeated in triplicate.
γ-H2AX foci formation. ES2 cell lines were cultured and seeded on sterile cover slips. Twentyfour hours following transfection with control or anti-endoglin siRNA, cells were exposed to 1μM cisplatin for either 1 or 4 hours, carefully rinsed to remove the drug, and cultured in regular media. Following the treatment period, IHC was performed as previously described [12] [13] Statistics. Analysis of normally distributed continuous variable was performed using a twotailed Student's t-test. Those data with alternate distribution were examined using a nonparametric Mann-Whitney U test. A p<0.05 was considered statistically significant.
Results
Effects of endoglin downregulation on cell viability and platinum sensitivity. Endoglin is expressed by multiple ovarian cancer cell lines ( Figure 1A ), most prominently in HeyA8, HeyA8MDR, and ES2 cells. Weak expression was detected in the HIO-180, A2780ip2, A2780cp20, SKOV3ip1, SKOV3TRp2, and IGROV-AF1 cell lines. This was previously demonstrated at the mRNA level by quantitative PCR 11 . To confirm that expression was predominantly at the cell surface, consistent with its function as a co-receptor for TGFβ, we performed immunohistochemistry on the ES2 and HeyA8MDR cell lines. Surprisingly, the predominant staining was noted n the perinuclear cytoplasm ( Figure 1B ). This was confirmed by flow cytometry, where interestingly not only was membranous staining rare, but there was a very distinct separate population with 100-fold fluorescent intensity (rather than a global shift among Figure 1B) . A separate endoglin-positive population has previously been noted in renal cell carcinoma cells, which did exhibit stem-cell properties. 18 However, these data are conclusive that the majority of endoglin expression in ovarian cancer is cytoplasmic, suggesting a role other than just as a co-receptor for TGF-beta.
To determine whether siRNA-mediated downregulation of endoglin had significant effects on viability and chemosensitivity, two different siRNA constructs (ENG_A siRNA and ENG_B siRNA) were examined. Both effectively reduced endoglin expression at 48 hours at the mRNA ( Figure 1D ) and protein level 11 ). Both were previously shown to reduce cell viability 11 . To determine the mechanism by which endoglin knockdown reduced viability, evaluation of apoptosis was performed by the TUNEL assay. Annexin V/PI co-fluorescent staining performed 48 hours following transfection indicated significantly fewer viable cells in those treated with anti-endoglin siRNA than those treated with control siRNA (47.2% vs. 65.1%, p<0.05). A sample flow cytometry plot and a graph of average over three experiments are shown in Figure   1D . Those treated with anti-endoglin siRNA had increased percentages of cells in both early apoptosis (21.5% vs. 17.9%, p<0.05) and late apoptosis (18.9% vs. 12.0%, p<0.05). Effects were more pronounced when combined with cisplatin. In order to determine whether Endoglin knockdown had an effect on viability in combination with chemotherapy, cells were exposed to siRNA, then re-plated after 24 hours, and incubated with increasing concentrations of cisplatin or paclitaxel. Because endoglin downregulation alone was associated with substantial cell death in the HeyA8MDR model, knockdown was performed with several dilutions of siRNA in an effort to more clearly delineate effects on platinum sensitivity. In both ES2 (normal IC50 for cisplatin = 0.7μM) and HeyA8MDR (normal IC50 for cisplatin = 0.65μM) models, increased cisplatin chemosensitivity was noted (up to 4-fold and 2-fold reduction in IC50, respectively, Figure 1E ).
Similar experiments were performed with paclitaxel, which did not show an increased sensitization with endoglin downregulation (data not shown).
Downregulation of endoglin induces DNA damage in vitro.
Because platinum toxicity is mediated primarily through induction of DNA damage, we evaluated whether the enhanced cisplatin sensitivity from endoglin knockdown was a result of increased DNA damage. DNA damaging agents can induce both single-stranded breaks (SSBs) and double stranded breaks (DSBs) which can lead to initiation of apoptotic pathways. DNA damage in the ES2 line was first assessed via an alkaline comet assay, which detects both SSB and DSB. As quantified in Figure 2A , increased DNA damage over 24 hours was observed with cisplatin, endoglin downregulation with siRNA, and the combination (although combination therapy was not significantly increased compared to either single-agent treatment). A representative section demonstrating common effects on nearly all cells is shown ( Figure 2B ). Because a long comet tail can be the result of either DNA damage without death or apoptosis-associated DNA release, the nucleus size was also quantified. A small nucleus would be associated with apoptosis, whereas a long comet tail associated with a normal (larger) nucleus would indicate just DNA damage. As shown in Figure 2C for cells treated for 24 hours, those cells with a long tail present predominantly still had a large nucleus. Because most toxic effects on viability noted previously were assessed at 48 hours or longer, this DNA damage may be a precursor to apoptosis 
induction. But it does demonstrate that DNA damage is the inciting event, rather than a result of apoptosis triggered by other mechanisms.
To further characterize the specific nature of DNA damage, development of foci of activated γ-H2AX was performed ( Figure 2D ). ES2 cells were employed, due to the rapid toxicity and cell death noted with endoglin downregulation with HeyA8. Phosphorylation of the histone protein H2AX on serine 139 (γ-H2AX) occurs at sites flanking DNA DSBs. The phosphorylation of thousands of H2AX molecules forms a focus in the chromatin flanking the DSB site that can be detected in situ. A higher proportion of cells with persistent γ-H2AX foci was noted with endoglin downregulation, to an even greater extent than cisplatin alone. The combination of cisplatin and endoglin downregulation induced more DSB repair than either agent alone. Collectively, these data suggest that a primary mechanism of DNA damage after endoglin downregulation is through induction of double-strand breaks in DNA.
Endoglin-targeting DNA damage is through effects on multiple mediators of DNA repair.
In order to determine the mechanism by which downregulation of endoglin induces DNA damage, we first subjected both ES2 and HeyA8MDR cells treated with control siRNA or endoglin-siRNA for 48 hours to a qPCR-based array of 84 genes participating in DNA damage and repair pathways. This exploratory analysis found multiple genes that were either downregulated or upregulated in response to decreased endoglin, some of which were only associated with changes in one cell line (Supplemental Table 1) . Select genes were then chosen for confirmatory assessment with qPCR ( Figure 3) . Genes for these analyses were selected based on the degree to which they were altered, the associated p-value, and whether the change was noted in both cell lines. With endoglin downregulation, significant concurrent downregulation 
was noted by qPCR in H2AFX (36-43%), BARD1 (47-71%), NBN (38-41%), NTHL1 (39-53%), and SIRT1 (34-49%). A significant induction of mRNA was noted in DDIT3 (1.9-2.6-fold) and PPP1R15A (1.27-1.74-fold). There was no single DNA repair pathway subclass that comprised all affected genes, but consistent with data from the γ-H2AX assay, most were participants in either the double stranded break repair (BARD1, H2AFX, NBN) or nucleotide excision repair (SIRT1, NTHL1).
The downregulation of BARD1 was particularly interesting. BARD1 is an oncogenic regulator of BRCA1, and downregulation would be expected to result in export of BRCA1 from the nucleus and impairment of DNA repair. Furthermore, BARD1 was noted to be significantly upregulated in chemoresistant tumor samples from patients, compared to their primary tumors.
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BARD1 expression is prominent in ES2 and HeyA8MDR, which follows if it is under transcriptional regulation by endoglin. Therefore, we examined BARD1 induction in response to platinum treatment in a progressively platinum-resistant triad of cell lines derived from A2780: A2780ip2 (which generates IP tumors more consistently than the parental line but is chemosensitive), A2780cp20 (having a platinum IC50 of 20μM), and A2780cp55 (with an IC50 of 55μM). The A2780cp20 and cp55 lines are stably platinum-resistant, and not chronically maintained in platinum. BARD1 expression is minimal in the parental A2780ip2 line, but increases at baseline ("Untreated") with each degree of platinum resistance ( Figure 3B ). Additionally, when exposed to an IC50 concentration of carboplatin, BARD1 mRNA production is significant increased in both A2780ip2 and A2780cp20. Levels were unchanged with carboplatin exposure in A2780cp55, likely due to its high baseline expression. A significant reduction in BARD1 with endoglin downregulation and an induction of BARD1 in response to platinum exposure strongly implicate this gene and its control on BRCA1 as a major mechanism through which endoglin downregulation may lead to DNA damage, apoptosis, and sensitivity to platinum.
In addition to enhanced DNA repair mechanisms, a major mechanism of platinum resistance is through increased export of platinum agents through copper transporters such as ATP7B. 19 Therefore we also examined the effects of endoglin downregulation on ATP7B by qPCR. SiRNA-mediated targeting of endoglin resulted in a significant downregulation of ATP7B (by 20-24%, p<0.05, Figure 3C ). While significant, this was not to the same extent many DNA repair genes were induced or activated.
Evaluation of tumor growth with anti-endoglin treatment in an orthotopic murine model.
In order to determine if endoglin downregulation was an effective therapy in vivo, an orthotopic murine model was utilized using human specific anti-endoglin siRNA delivered within a chitosan nanoparticle. Chitosan (CH) is a natural nanoparticle that has been previously demonstrated to result in efficient delivery of siRNA to tumor after IV administration, with subsequent protein downregulation and gene-specific modulation. 16, [20] [21] [22] Because the siRNA delivered is specific to the human endoglin mRNA, any observed effect would be expected to be due to targeting the tumor cells, rather than the vasculature, which would require murine-specific siRNA. ES2 and HeyA8MDR cells were injected IP, and treatment was started 1 week later with a) control siRNA-CH alone, b) control siRNA-CH plus carboplatin, c) anti-endoglin siRNA-CH alone, or d) anti-endoglin siRNA-CH plus carboplatin. Carboplatin was used instead of cisplatin because of its preferable side-effect profile in vivo, which has led to its choice as standard of care in ovarian cancer patients. Tumors demonstrated reduced growth both with endoglin downregulation alone and in combination with platinum. In the ES2 model ( Figure 4A Figure 5A) . A lack of effect on progression through the cell cycle and proliferation may explain why combination with taxanes was not synergistic with endoglin downregulation in vitro. TUNEL assay was performed to evaluate to detect differences in apoptosis between treatment groups. Control, carboplatin and anti-endoglin siRNA groups were not significantly different. However, the cohort receiving combination therapy had a significantly higher percent of apoptotic cells when compared to control (p<.001, Figure 5B ). This increase, though statistically significant, is relatively small, which may be due to clearance of dead cells over the course of the 4-week experiment. To determine if DNA damage was still noted in the tumors collected at completion of therapy, fluorescent IHC was performed to evaluate for γ-H2AX as an indicator of in vivo DSB. A significantly higher amount of DNA damage was detected in both treatment groups receiving anti-endoglin treatment than either control or single-agent carboplatin treatment ( Figure 5C ). Additionally, 53BP1 is a mediator of DNA damage response and a tumor suppressor whose accumulation on damaged chromatin promotes DNA repair and enhances DNA damage response signaling. A significantly higher number of 53BP1-positive cells was noted in both cohorts that received anti-endoglin treatment when compared to either control or single-agent platinum ( Figure 5D ). These data are consistent with in vitro studies demonstrating that endoglin downregulation alone leads to DNA damage and apoptosis.
Discussion
Endoglin is overexpressed in solid tumor vasculature and is a reliable marker of angiogenesis. The primary canonical role of endoglin is as a co-receptor for TGF-beta. [24] [25] [26] As such, its expression on endothelial cells is primarily on the cell membrane. 27 However, we interestingly found endoglin expression in ovarian cancer cells was predominantly cytoplasmic, and clustered together in the perinuclear region of the cell. This would suggest that endoglin either has a separate TGF-beta-independent function dependent on nuclear proximity, or trafficking to the cell membrane is an important component of its regulation. Only a small (5-6%), but welldefined population had surface expression. This distinct population would be consistent with a cancer stem cell-like population, as has been previously described in endoglin-positive renal cell carcinoma 18 . Endoglin-positive meningioma cells have similar increased tumorigenicity and capacity to differentiate into adipocytes and osteocytes. 28 Henriksen et al. evaluated endoglin expression in primary ovarian cancer cells and found that high tumor cell endoglin staining correlated with short overall survival. 29 Another group has shown that cells from cultured ascites that progressed towards a mesenchymal phenotype were high in endoglin. 30 We identified endoglin as a potential target for therapeutics through a screen 
of stem cell pathways overexpressed in recurrent ovarian cancer samples. Among members of the TGF-β, Notch, Wnt, and Hedgehog pathways, endoglin was most significantly and consistently overexpressed in recurrent ovarian cancer samples when compared to their matched primaries, suggesting a role in chemoresistance. 11 We specifically examined stem cell pathways to address the question of whether the cancer stem cell population may be responsible for surviving initial chemotherapy. Endoglin has previously been implicated in stem cell biology, having originally been described on hematopoietic progenitor cells 31 , and later demonstrated to identify precursor cells capable of tissue-specific differentiation [32] [33] .
It makes sense that cells with prolonged survival, such as stem/progenitor cells, would reply on pathways to mediate DNA damage. Because of the association noted with increased endoglin expression in platinum (and taxane)-resistant recurrent ovarian cancers, 11 and the contribution of enhanced DNA repair for platinum resistance, 19 we further examined the contribution of endoglin to DNA repair. We have found a previously unknown contribution of endoglin to expression of numerous DNA repair genes. These encompass several subtypes of DNA repair, predominantly double stranded break repair (BARD1, H2AFX, NBN), but also nucleotide excision repair (SIRT1, NTHL1), and cell cycle arrest (DDIT3, PPP1R15A), which may be a reactionary process in order to accomplish DNA repair. Recently BARD1 has been implicated in ovarian cancer pathogenesis for its interaction with BRCA1 and 2. BARD1 and BRCA1 interact with each other through their amino terminal RING finger domains. This interaction is required for BRCA1 stability, as well as for nuclear localization. The BRCA1-BARD1 complex serves as an E3 ubiquitin ligase, which has been noted to have critical activity in both the cell cycle check point through H2AX, NPM and γ-tubulin and in DNA fragmentation. [34] [35] Additionally, patients with mutations of both BARD1 and BRCA2 have a 
substantially increased risk for development of both breast and ovarian cancer. While BARD 1 has been found to interact and co-localize with BRCA1 at the spindle poles in early mitosis, it also interacts with BRCA2 at late mitosis in the midbody. Therefore BARD1 has been found to sequentially link the function of these 36 two proteins. In our analysis, BARD1 expression was reduced by 50-75% and H2AX expression was reduced 35-50% following endoglin knockdown.
endoglin-mediated downregulation of BARD1 and its subsequent effects on BRCA1 and 2 and H2AX may therefore explain why we found substantial decreased cell viability, DNA damage and increased apoptosis.
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Silent Information Regulator Type 1 (SIRT1) is a nicotinamide adenine dinucleotidedependent class III histone deacetylase (HDAC). SIRT1 has is associated with longevity and has been found to act primarily by inhibiting cellular senescence. SIRT1 is up-regulated in tumor cell lines and human tumors, and may be involved in tumorigenesis. 36 It has also been found to be over-expressed in chemoresistant tumors of cancer patients. SIRT1 inhibition leads to decrease in MDR1 expression and increase in drug sensitivity in ovarian cancer cell lines. 37 Our research suggests that Endogin knockdown was associated with a 30-50% reduction in SIRT1. This inhibition may help account for the increased platinum sensitivity we found with endoglin downregulation.
In regards to therapeutic development in cancer patients, delivery of siRNA constructs has the potential to offer long duration of target inhibition as well as reduced toxicity compared other approaches. 16, 20, [38] [39] [40] [41] [42] [43] [44] However, development of a delivery modality for siRNA constructs remains the rate-limiting step in translational research. Early delivery modalities included of chitosan encapsulation and nanoliposomes to deliver siRNA has become widely accepted in translational studies and is and promising as a therapeutic modality as modifications to enhance in vivo delivery progress. 22 SiRNA mediated therapeutics are being used in ongoing trials with patients with macular degeneration, AIDS, malignant melanoma, acute renal failure, hepatitis B, and now in cancer patients, where phase I trials are in development. One particular advantage of siRNA-based therapeutics over conventional treatment modalities would apply to endoglin-based targeting. If indeed the cytoplasmic portion of endoglin is important to chemoresistance, downregulation of production at the mRNA level may be more effective than antibody-based targeting currently aimed at inhibiting angiogenesis. [45] [46] Because of the rarity of endoglin expression in normal tissues, anti-endoglin therapy has the potential to offer tumor-directed therapy in addition to anti-angiogenic therapy. Antiendoglin therapy is being explored as a therapeutic in several cancers as an anti-angiogenic agent. In ovarian cancer, endoglin-targeted therapies may offer the additional advantage of targeting tumor cells overexpressing endoglin, including platinum-resistant tumors. Its effects on BRCA1 and 2 and H2AX through BARD1 downregulation, and its association with SIRT1 downregulation contribute to DNA damage repair and enhancement of platinum sensitivity. Our data strongly suggest that endoglin-targeted therapy has the potential to improve platinum sensitivity through induction of DNA damage and should be actively pursued as a potential therapy in the treatment of ovarian cancer. Each collection was performed in triplicate, and the mean change over housekeeping gene presented. Significant decreases were noted in H2AFX, BARD1, NBN, NTHL1, and SIRT1.
Induction of DDIT3 and PPP1R15A was also significant. B) BARD1 mRNA was assessed by qPCR in a triad of progressively platinum-resistant A780 cell lines, and noted to be significantly increased in A2780cp55 at baseline, and in A2780ip2 and A2780cp20 with exposure to carboplatin. C) The copper transporter ATP7B was also modestly, but significantly, reduced with endoglin downregulation. 
